Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808066 · ClinicalTrials.gov registry record · NA
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
A NA study of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder, sponsored by CogCubed.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01808066: Completed NA study of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder, sponsored by CogCubed.
NCT01808066 is a NA study of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder that has completed, run by CogCubed. The registered enrollment target is 21 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01808066, a NA study of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder, has completed, sponsored by CogCubed.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the use of, and reaction to, one particular software application(GroundsKeeper) delivered on unique platform - Sifteo cubes (www.sifteo.com). The hypothesis is that the use of these devices will increase engagement, motivation, interest, and have perceived benefits to users with unique attention-limiting cognitive disabilities. How does the observation of and user feedback from gameplay reveal areas of improvement for the game, strengths, and perceptions of value among the players and adults?
Primary Outcome
Researchers will observe and record data during the first play session. Over the three weeks, teachers/support staff will be asked to observe players each day and record their observations as needed in a journal. These observations will measure their improvement in their ability to focus by assessing their engagement, time played, frequency of play, ability to complete a session and ability to start and finish a session. At the end of three weeks, researchers will attend the final play session a
Conditions Studied
Interventions
- DEVICE Groundskeeper
Study Locations (1)
Ohio
- Ohio University - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-05 |
| Phase | NA |
What the finished NCT01808066 record still lists
NCT01808066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Groundskeeper is the first listed.
NCT01808066 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01808066 about?
NCT01808066 is a clinical study titled "GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs". The purpose of this study is to examine the use of, and reaction to, one particular software application(GroundsKeeper) delivered on unique platform - Sifteo cubes (www.sifteo.com). The hypothesis is that the use of these devices will increase engagement, motivation, interest, and have perceived ben...
What is the current status of trial NCT01808066?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2013-01. Estimated completion is 2013-05.
What conditions does trial NCT01808066 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Pervasive Developmental Disorder, Asperger's Disorder.
What interventions are being tested in trial NCT01808066?
The interventions under investigation include: Groundskeeper (DEVICE).
Who is sponsoring clinical trial NCT01808066?
This trial is sponsored by CogCubed, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01808066 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01808066's enrollment target sits among peer trials
21 197th of 224 higher than 26 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Milieu Teaching-AV (MT-AV Pilot)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia